採用
Alnylam

Alnylam
Focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
RNA Interference
Gene Therapy
Drug Development
Biomedical Research
募集中のポジション
0件のポジション
現在募集中のポジションはありません
製品・サービス
ON
ONPATTRO (patisiran)
Commercial Drug

ONPATTRO (patisiran)
RNAi Therapeutic

GIVLAARI (givosiran)
RNAi Therapeutic
GI
GIVLAARI (givosiran)
Commercial Drug
OX
OXLUMO (lumasiran)
Commercial Drug

OXLUMO (lumasiran)
RNAi Therapeutic

AMVUTTRA (vutrisiran)
RNAi Therapeutic
AM
AMVUTTRA (vutrisiran)
Commercial Drug
LE
LEQVIO (inclisiran)
Partnered Drug

LEQVIO (inclisiran)
RNAi Therapeutic
RN
RNAi Platform Technology
Technology Platform

RNAi Platform Technology
Technology Platform

Cemdisiran
Pipeline Drug
CE
cemdisiran
Pipeline Drug
FI
fitusiran
Pipeline Drug

ALN-APP
Pipeline Drug

Fitusiran
Pipeline Drug

Drug Development Services
Services
類似企業

Labcorp
Public
Leading company in the healthcare industry
Burlington, North Carolina
10,001+
Valuation $13.2B
1441 open jobs

Invitae
Public
Biotechnology company.
San Francisco, CA
501-1,000

Molina Healthcare
Public
Care company.
Long Beach, California, United States
10,001+
Valuation $4.2B

Medtronic
Public
Medical device company.
Minneapolis, Minnesota, United States
10,001+
Valuation $100B
875 open jobs

AbbVie
Public
Pharmaceutical company.
North Chicago, Illinois
10,001+
Valuation $200B
364 open jobs

Cerner (Oracle)
Acquired
Cloud applications and platform services.
Austin, Texas
10,001+
Valuation $28.3B
ニュース&話題
All
X
News
HN
YouTube
GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
MarketBeat
News
·
3日前
Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset - Quiver Quantitative
Quiver Quantitative
News
·
4日前
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
·
5日前
·
1
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results - Business Wire
Business Wire
News
·
5日前
KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
MarketBeat
News
·
5日前
もっと見る (残り15件)
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
レビュー
4.3
10件のレビュー
ワークライフバランス
3.8
報酬
3.2
企業文化
4.5
キャリア
3.7
経営陣
4.1
78%
友人に勧める
良い点
Supportive team and colleagues
Good benefits package
Flexible work arrangements
改善点
High workload and intensity
Limited career advancement
Compensation concerns
給与レンジ
69件のデータ
Director
Intern
Mid/L4
Senior/L5
Director
1件のレポート
$231,400
年収総額
基本給
$178,000
ストック
-
$231,400
$231,400
面接体験
3件の面接
難易度
3.0
/ 5
期間
2-5w
体験
ポジティブ 0%
普通 33%
ネガティブ 67%
面接プロセス
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Round Interview
6
Offer
連絡先・所在地